237 related articles for article (PubMed ID: 28663581)
1. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.
Michallet M; Chapuis-Cellier C; Dejoie T; Lombard C; Caillon H; Sobh M; Moreau P; Attal M; Avet-Loiseau H
Leukemia; 2018 Feb; 32(2):376-382. PubMed ID: 28663581
[TBL] [Abstract][Full Text] [Related]
2. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
[TBL] [Abstract][Full Text] [Related]
4. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
5. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
8. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
10. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.
Fouquet G; Snell KI; Guidez S; Schraen S; Boyle E; Renaud L; Desmier D; Machet A; Moya N; Systchenko T; Gruchet C; Decaux O; Arnulf B; Fohrer C; Richez V; Kolb B; Macro M; Karlin L; Royer B; Pegourie B; Hebraud B; Caillot D; Perrot A; Moreau P; Facon T; Avet-Loiseau H; Dejoie T; Hulin C; Harding S; Leleu X
Leuk Lymphoma; 2018 Mar; 59(3):583-589. PubMed ID: 28697637
[TBL] [Abstract][Full Text] [Related]
11. [Effect of immunoglobulin heavy/light chain detection on the minimal residual disease monitoring in IgG multiple myeloma patients].
Zhang H; Zhou L; Li R; He J; Peng Z; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):95-8. PubMed ID: 25778881
[TBL] [Abstract][Full Text] [Related]
12. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
13. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.
Katzmann JA; Willrich MA; Kohlhagen MC; Kyle RA; Murray DL; Snyder MR; Rajkumar SV; Dispenzieri A
Clin Chem; 2015 Feb; 61(2):360-7. PubMed ID: 25451866
[TBL] [Abstract][Full Text] [Related]
14. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome.
Wang C; Su W; Cai QQ; Cai H; Ji W; Di Q; Duan MH; Cao XX; Zhou DB; Li J
Eur J Haematol; 2016 Jul; 97(1):48-54. PubMed ID: 26383741
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
17. Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.
Suehara Y; Takamatsu H; Fukumoto K; Fujisawa M; Narita K; Usui Y; Takeuchi M; Endean K; Matsue K
Cancer Sci; 2017 Feb; 108(2):187-192. PubMed ID: 27889936
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
[TBL] [Abstract][Full Text] [Related]
19. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
20. Analytical validation of the Hevylite assays for M-protein quantification.
Jacobs JFM; Haagen IA; Lodder A; van der Kroft C; de Kat Angelino CM; Croockewit S; Nieuwenhuys E; Gelderman KA
Clin Chem Lab Med; 2018 Jun; 56(7):1169-1175. PubMed ID: 29397379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
